PCM
VRTX icon

Prelude Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Prelude Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-7,300
Closed -$691K – 2156
2014
Q2 		$691K Buy
7,300
+6,300
+630% +$442K 0.09% 278
2014
Q1 		$71K Buy
1,000
+100
+11% +$7.92K 0.01% 1162
2013
Q4 		$67K Buy
+900
New +$62.7K 0.01% 981

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Prelude Capital Management's VRTX Position: Q1 2026 in Review

Prelude Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 463 shares — an estimated $210K sold.

Prelude Capital Management first reported a position in VRTX in Q2 2013 and held it in 40 quarters. The position peaked at $5.43M in Q2 2018. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Prelude Capital Management reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 463 Vertex Pharmaceuticals shares in Q1 2026, an estimated $210K.
  • Prelude Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 40 quarters.
  • Prelude Capital Management's Vertex Pharmaceuticals position peaked at $5.43M in Q2 2018.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.